@xconomy.com 1 month ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com 6 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 7 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 9 months ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com 1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 1 year ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 1 year ago
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan
@xconomy.com 1 year ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com 1 year ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 1 year ago
San Antonio Life Science Business Acelity Cuts 260 Jobs in Texas, NC
@xconomy.com 1 year ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com 1 year ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com 1 year ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 1 year ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More